EntryPoint Capital’s Myriad Genetics MYGN Stock Holding History

EntryPoint Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227K	Buy	+39,837	New	+$181K	0.06%	649
2025 Q3	–	Sell	-38,634	Closed	-$205K	–	803
2025 Q2	$205K	Buy	38,634 +8,480	+28%	+$50.1K	0.1%	476
2025 Q1	$267K	Sell	30,154 -19,732	-40%	-$237K	0.12%	392
2024 Q4	$684K	Buy	+49,886	New	+$920K	0.29%	31
2024 Q1	–	Sell	-2,819	Closed	-$54K	–	1639
2023 Q4	$54K	Buy	+2,819	New	+$48.8K	0.05%	679

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EntryPoint Capital's MYGN Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Myriad Genetics (MYGN) in Q2 2026: 39,837 shares worth $227K. The stake represents 0.06% of the portfolio and ranks #649 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in MYGN as recently as Q2 2025.

EntryPoint Capital first reported a position in MYGN in Q4 2023 and has held it in 5 quarters since. The position peaked at $684K in Q4 2024. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

EntryPoint Capital held 39,837 shares of Myriad Genetics worth $227K as of Q2 2026.
Myriad Genetics was a new EntryPoint Capital position in Q2 2026.
Myriad Genetics made up 0.06% of EntryPoint Capital's portfolio in Q2 2026, its #649 holding.
EntryPoint Capital first reported a position in Myriad Genetics in Q4 2023 and has held it in 5 quarters since.
EntryPoint Capital's Myriad Genetics position peaked at $684K in Q4 2024.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.